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Abstract
It is well known that hydrophobic small molecules penetrate cell membranes better than
hydrophilic molecules. Amphiphilic molecules that dissolve both in lipid and aqueous phases are
best suited for membrane transport. Transport of biomacromolecules across physiological barriers,
e.g. the blood-brain barrier, is greatly complicated by the unique structure and function of such
barriers. Two decades ago we adopted a simple philosophy that to increase protein delivery to the
brain one needs to modify this protein with hydrophobic moieties. With this general idea we began
modifying proteins (antibodies, enzymes, hormones, etc.) with either hydrophobic fatty acid
residues or amphiphilic block copolymer moieties, such as poy(ethylene oxide)-poly(propylene
oxide)-poly(ethylene oxide) (pluronics or poloxamers) and more recently, poly(2-oxasolines). This
simple approach has resulted in impressive successes in CNS drug delivery. We present a
retrospective overview of these works initiated in the Soviet Union in 1980s, and then continued
in the United States and other countries. Notably some of the early findings were later
corroborated by brain pharmacokinetic data. Industrial development of several drug candidates
employing these strategies has followed. Overall modification by hydrophobic fatty acids residues
or amphiphilic block copolymers represents a promising and relatively safe strategy to deliver
proteins to the brain.
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The challenge of the delivery of the therapeutic proteins to the brain is well recognized. Poor
serum bioavailability of many proteins during systemic circulation combined with their low
permeability across the blood-brain barrier (BBB) tremendously limit the effective amounts
of these proteins that can enter the brain. Extensive efforts have been devoted to improve
protein delivery to the brain to address various diseases of the central nervous system (CNS)
as reviewed herein and elsewhere [1–5]. Thus, intranasal administration, for example, has
recently become a promising strategy to deliver proteins and other biotherapeutics to the
brain as it allows bypassing the BBB and minimizing peripheral tissue exposure [6–9].
Another recent example is the use of a bispecific antibody with low-binding affinity to the
transferrin receptor, which displays high permeability across the BBB (contrary to the high
affinity antibodies that are entrapped in the brain endothelium) [10,11]. Moreover, there is a
growing effort in using nanotechnologies in the CNS delivery field, which aims to improve
stability and pharmacokinetics (PK) of proteins by encapsulating them in nanoparticles and
further increase their brain uptake using BBB specific targeting moieties [12–20]. The field
keeps moving forward as the investigators gain better understanding of the BBB biology and
acquire experience in developing delivery systems for CNS diseases.
This paper reviews some of our own efforts to deliver proteins to the brain, involving
chemical modification of proteins by fatty acid residues and block copolymer amphiphiles.
Along with retrospective overview of these studies spanning over two decades this paper
covers multidisciplinary approaches ranging from synthesis, cell entry and trafficking, PK
and brain distribution, and finally to the evaluation of efficacy in relevant CNS disease
models. While continuing our work to improve protein delivery to the brain, we aim to share
the knowledge and experience of the state of the art in each of these approaches, which
hopefully will disseminate and advance an in-depth understanding of these strategies for
protein delivery to the brain.
Artificial fatty acid acylation of proteins
Fatty acid acylation is a common step in endogenous modification of proteins serving to
regulate protein interaction with membranes and influence protein sorting within cells [21–
24]. In early 80 s Torchilin’s group has applied artificial lipid and fatty acid modification of
proteins to immobilize them within the liposomal membranes [25]. The idea of artificial
hydrophobization of proteins by fatty acid residues to enhance protein delivery into cells and
to the brain goes back to late 1980s [26–28]. Such fatty acylated proteins exhibit increased
ability to anchor to cell membranes (which sometimes involves interaction with fatty acid
binding membrane proteins) and enhanced internalization in cells [29]. This seems to remain
true in the case of the brain microvessel endothelial cells (BMEC), which comprise the
BBB. Interestingly, early work by the Chekhonin and Kabanov groups showed that fatty
acid acylation only improved brain accumulation of the proteins that can specifically bind
with the receptor expressed within the brain [26]. For those brain non-specific proteins, the
fatty acid acylation resulted in increased accumulation in liver rather than in the brain. This
was evidenced by C18 fatty acid (stearic acid) acylation of two brain specific antibody
fragments, Fab against glial fibrillary acidic protein (Fab-GFAP) and Fab against α2-
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glycoprotein (Fab-α2-GP), and two brain non-specific antibody fragments, Fab against α1
and α2 human globulins (Fab-α1-IgG and Fab-α2-IgG). To examine the therapeutic
response, a neuroleptic drug, trifluoperazine, was attached to these antibody fragments.
Intracarotid injection of iodine labeled stearylated Fab- GFAP and Fab-α2-GP to rat model
showed significantly increased (versus unmodified Fab-GFAP and Fab-α2-GP)
accumulation of the modified fragments in the brain, followed by in the heart and in the
lung. In contrast iodinated stearylated Fab-α1-IgG and Fab-α2-IgG distributed much better
(versus unmodified Fab-α1-IgG and Fab-α2-IgG) in the liver, followed by in the spleen and
in the lung. The pharmacodynamic response appeared to corroborate the PK data as a drastic
increase of the neuroleptic activity was observed only with the stearylated brain specific
antibody fragments. Slepnev and Kabanov followed-up these in vivo works and further
examined in various of mammalian cell models how fatty acylated horseradish peroxidase
(HRP), a membrane impermeable enzyme and a well known endocytosis marker, interacted
with cells [29]. They confirmed that fatty acylation increased cellular binding and
internalization of HRP, to a greater extent in the presence of serum (than without serum) and
at 4 °C (than 37 °C). Internalized fatty acylated HRP was mainly distributed in endocytic
vesicles and less noticeable in cytoplasm [29]. In a transport study using bovine BMEC
(BBMEC) monolayer, Chopineau demonstrated that the permeability of monoacylated
ribonuclease A correlated with the length of the acyl chain; as the carbon chain became
longer the permeability across the cell monolayer increased [30]. Subsequently, the Kabanov
and Banks groups reported on the brain PK of fatty acylated HRP [31]. They demonstrated
that stearylated HRP was able to cross the BBB at a higher influx rate than native HRP. The
serum half-life was not altered by fatty acylation. Direct measurement of liver accumulation
was not reported in this paper. However, based on the serum clearance curve, the volume of
distribution of stearylated HRP was much higher than that of the native HRP, suggesting
that the stearylated protein sequestered in tissues. Again, a minimum increase was seen in
brain uptake, consistent with what was shown previously for non-specific brain antibodies
[26].
Interest to protein delivery to the brain using fatty acylation was dampened by an additional
challenge encountered at that time: experimental difficulties in attaching hydrophobic fatty
acids to water-soluble proteins. Reacting hydrophobic reagent with hydrophilic protein
generally does not proceed well in an aqueous medium even in the presence of a detergent
(e.g., sodium cholate) (Figure 1A and B). Indeed, only 20% of α-chymotrypsin was
modified by stearoyl chloride in water and the modified fraction was highly heterogeneous
containing from 6 to 12 stearoyl groups per protein molecule [27]. Reacting protein/peptide
with fatty acid directly in organic solvent is not recommended because of protein
inactivation and solubility issues (Figure 1C). Modification was then carried out in aqueous
microemulsions stabilized by a surfactant, sodium bis-(2-ethylhexyl) sulfosucciate (Aerosol
OT) in the water-immiscible organic solvent, octane [32,33] (Figure 1D). In such
microheterogeneous medium also sometimes termed “hydrated reverse micelles” at the same
molar ratio of stearoyl chloride to proteins, more than 80% protein was modified with 1 to 2
stearoyl groups per protein [27]. Unfortunately exposing proteins to organic solvents in this
reverse micelles system led to a significant loss of the activity for most of proteins. Only 15–
25% of the activity remained in fatty acylated trypsin [27], 50% in stearoylated HRP [29]
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and 60–80% in stearoylated α-chymotrypsin [27]. Additionally, removal of the remaining
surfactant from the final fatty acylated proteins was not trivial, albeit realizable by
precipitation in acetone and chromatography method [34].
Nevertheless, the effort to develop fatty acylated proteins has continued and not
surprisingly, was more appreciated for treating peripheral diseases or conditions where the
peripheral pathological mechanism is partially involved. Soviet Union researchers
continuously carried out the work by modifying pig leukocyte interferon with steroid acid
using similar reverse micelle systems. Following i.v. administration in poultry and cattle, the
modified interferon showed a drastic decrease in viral titer (up to a million fold) and a
significant improvement in its protective activity against various pathogens, in comparison
to animals treated with interferon alone [32]. Investigators also noted nearly a thousand-fold
decrease in the proliferation of human Jurkat T-lymphoma cells upon treatment with
palmitoylated human recombinant α2-interferon versus incubation with native α2-interferon
[35]. Similarly, the toxic effect of Staphylococcus aureus enterotoxin A on Jurkat T-
lymphoma and peripheral blood lymphocytes was considerably amplified when enterotoxin
A was modified by strearic acid [36]. In the same publication, the author also demonstrated
that stearylated ricin A chain, a protein that was initially inactive due to lack of penetration
into cells, acquired considerable activity in inhibiting protein biosynthesis and cell
proliferation in the lymphoma cells. This provided additional evidence that fatty acylation of
selected proteins can increase their transport into cells.
With this rationale Kabanov et al. used the fatty acylation approach to increase antiviral
activity of the antibodies against several viruses. Thus, stearylation of polyclonal and
monoclonal antibodies against the influenza virus hemagglutinin (HA) and the influenza
virus nucleoprotein (NP) suppressed the reproduction of various influenza viruses by one to
three orders of magnitude in the infected cell culture [37]. A similar phenomenon was
observed using the stearylated polyclonal antibodies against the respiratory syncytial virus,
which displayed decreased capability to infect MDCK cells compared to that of unmodified
antibodies. It was proposed that by anchoring in the membranes of virus-infected cells
through the fatty acid moieties, the modified antibodies were able to interfere with the self-
assembly and/or budding of the respective viral particles. Furthermore, the attenuation of
viral growth in the infected cells could also attribute to the penetration of modified antibody
into the cells and thereby serve as an intracellular antigen to interfere with the virus cycle.
Subsequent animal studies further supported the therapeutic improvement for fatty acylated
antibodies against virus infection. The effect of stearylated or unmodified monoclonal
antibodies against the glycoprotein gD of the herpes simplex virus 1 (HSV1) was evaluated
in pre-infected mice that developed lethal herpetic meningitis or generalized herpetic
infection. Following intracerebral injection (to treat meningitis) or intraperitoneal injection
at various doses for 5 d (to treat generalized infection), the modified antibodies decreased
the mortality in both disease models by about 60%, while the effects of the unmodified
antibodies did not exceed 30%. In spite of the observed improvement in both in vitro and in
vivo studies we listed above, the fundamental mechanism of fatty acylation to facilitate
protein therapeutics has not been well illustrated.
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More recently, development of fatty acylated proteins have focused on treatment of liver
diseases, which is rationalized by the liver targeting effect as a consequence of fatty
acylation. Wei-Chiang Shen and colleagues introduced four C16 fatty acid (palmitic acid)
moieties to the cysteine amino acids of interferon α, a most effective antiviral agent for
chronic viral hepatitis [38]. The reaction appeared to proceed well in phosphate saline buffer
supplemented by 0.5% Chaps detergent. About 90% of the protein was modified and no
dramatic changes were observed in the secondary structure of the modified interferon α,
albeit its remaining activity was not reported. Following fatty acylation, intravenous
administration of iodinated interferon α showed much longer serum circulation and higher
liver accumulation than the native form. The augmentation of the in vivo antiviral effect was
also demonstrated in mice receiving fatty acylated interferon. It probably would be more
appealing if these studies included the comparison with PEGylated interferon α, the most
widely used product for liver hepatitis. Provided the liver-targeting effect and the capacity to
be taken up by hepatocytes are exhibited in the fatty acylated interferon α, it could be a
promising candidate to treat liver hepatitis [38]. A study conducted by Kathrin Bellmann-
Sickert using pancreatic polypeptide (PP) as an example could partially highlight the
advantage of lipidation over PEGyation to target proteins to the liver [39]. In this study the
modification of PP by a single palmitoyl moiety resulted initially in increased high blood
content of the modified peptide followed by its tissue sequestration throughout the whole
body with predominant localization in the heart and finally distribution of this peptide
exclusively in the liver. In contrast, native PP or PP modified with PEG (2 KDa) was
exclusively excreted from the kidney, resulting in a much shorter plasma residence than that
of palmitoylated PP.
The examples of fatty acid acylated proteins for brain delivery are presented in Table 1. As
of today perhaps the most advanced application of artificial fatty acid acylation of proteins
for drug delivery is the development of long acting anti-obesity hormones. Gut-brain
hormones originate from the gut-intestine tissue and act partially or exclusively within the
CNS to control appetite and energy consumption. These polypeptide hormones often have
less than 30 amino acids. They exert their biological function either via systemic circulation
and delivery into the brain and/or communicating with the brain via the vagal nerve [50].
There is a growing awareness that these hormones along with circulating nutrients and
neuronal peptides modulate appetite, feeding and metabolism [51–54]. Therefore they
provide a range of therapeutic opportunities for treatment of metabolic disorders (e.g
diabetes, obesity, etc.) [55,56]. Interestingly, fatty acid acylation of gut-brain hormones is a
naturally occurring phenomenon. Octanoic acid acylated ghrelin, 28-amino acid peptide,
acts as an important cognate ligand to stimulate growth hormone release and regulate energy
hemostasis [42]. Specifically, O-n-octanoylation of ghrelin at the serine 3 position, a post-
translational reaction catalyzed by ghrelin O-acyltransferase (GOAT) (Figure 1E), is
indispensible for the hormone binding to and activation of the growth-hormone secretagogue
receptor [41,44]. This is an essential step in initiating the multifaceted endocrine function of
ghrelin. It appears that the pharmacological role of the post-translational modification of
ghrelin with octanoic acid mainly involves the modulation of the hormone-receptor
interactions rather than altering the PK of the hormone and its passage across the BBB
[40,43]. However, the brain PK study did show that octanoylation of ghrelin has a dramatic
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effect on its transport characteristics across the BBB [40]. Although the improved brain
delivery of the octanoylated ghrelin so far was not implicated in its physiological function,
the fact that such natural modification takes place negates some safety concerns for fatty
acylation of polypeptides and sheds light on the potential to influence their brain PK using
this approach.
Moreover, since short sequence peptides are produced by solid-phase synthetic strategies,
the fatty acid chains can be introduced in the gut-brain hormones in a robust and controllable
fashion during the peptide synthesis circle followed by cleavage of the modified peptide
from the resin, allowing for a clean product with minimum activity loss [39,48] (Figure 1F).
This is an important factor that has facilitated and possibly will continuously inspire
development of fatty acylated gut-brain hormones as therapeutic drugs. Liraglutide, a
glucagon-like peptide 1(GLP-1) analog modified with a C16 fatty acid chain is currently
tested in Phase III as an anti-obesity drug [46,57]. Owing to the notable improvement in its
PK profile (longer circulation, smaller volume distribution), this daily subcutaneously
administered GLP-1 analogue is a promising drug candidate to replace exenatide, a native
form of GLP-1, which must be given twice daily. It is beyond the scope of this article to
compare in-depth the efficacy and risk of liraglutide and exenatide. Simply saying, the
efficacy of liraglutide seems to improve while there was not an identifiable decrease in
polypeptide tolerability [45,46]. Interestingly, most of the gut-brain hormones including
GLP-1 control appetite and thermogenesis at two sites: peripherally by signaling the vagal
nerve surrounding gut-intestine and centrally by simultaneously acting at their central
receptors after circulating to the brain. Animal studies have provided clear evidence that the
anti-obesity effect of exogenously delivered exenatide and liraglutide was a combination of
their action at both peripheral and central sites [47]. However, in spite of improvement in the
hormone’s peripheral circulation, no brain PK data were reported to support the role of fatty
acylation to increase GLP-1 brain uptake.
Nevertheless, the strategy has been extended to deliver α-melanocyte-stimulating hormone
(α-MSH), a tetradecappeptide that acts within the brain and regulates energy expenditure via
melanocortin system. To overcome the short serum half-life of native α-MSH, Novo
Nordisk developed an α-MSH analog with N-terminal attachment of the C16 fatty acid [48].
The serum half-life of α-MSH as a result of its modification with palmitic acid was
increased allowing for a once-daily injection of the modified hormone to attain adequate
therapeutic response. In an acute feeding study, this long acting α-MSH analog displayed a
prolonged response of food reduction following a single subcutaneous administration in
normal body weight male Sprague–Dawley rats (48 h versus 7 h in unmodified hormone).
Albeit the brain PK study on this palmitoylated α-MSH was not reported, Novo Nordisk
conducted the preclinical and clinical studies of fatty acylated α-MSH named MC4-
NN2-0453 in obese model. While in obese mini-pigs, MC4-NN2-0453 showed a better
response than unmodified α-MSH in reduction of energy expenditure and food intake, the
clinical trial of this fatty acylated α-MSH analog, however, did not show any clinically
meaningful change in obese patients and did not succeed due to the pharmacological side
effect associated with hyperpigmentation [49]. Development of other anorexigenic
neuropeptides by fatty acylation is also underway. Prolactin-releasing peptide (PrP), a 31
amino acid anorexigenic neuropeptide acts exclusively in the brain to regulate energy
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expenditure. Maletinska et al. produced a fatty acylated PrPR in order to elongate the
circulation circulation time of this polypeptide and increase its permeability at the BBB. The
data were reported as a conference abstract showing fatty acylated PrPR had stronger effects
in fasted mice following subcutaneous administration [58].
Despite growing evidence that fatty acylation improves protein therapeutics acting at both
peripheral and central sites, understanding the mechanism of the increased transport of fatty
acylated proteins at the BBB level lagged behind. Fatty acylation as an endogenous process
to regulate the reversible membrane association and intracellular signaling has been well
elucidated [23]. Strongly depending on the attached fatty acid (type, length, the amount per
protein) and the nature of protein (charge, binding ligand, phosphorylation, co-factor), fatty
acylated endogenous proteins penetrate the cell membranes in various manners, with
different efficiencies, and have various destinations inside cells [23]. To advance the
delivery for brain targeting, there is a need to understand how these mechanisms come into
play at the brain endothelium level. For example, the binding of fatty acylated proteins to
cell membrane is generally driven by hydrophobic interactions. At the BBB, a transporter-
mediated mechanism might play a role when the attached fatty acids, such as linoleic acid,
are naturally transferred to the brain by transporters [59,60]. The luminal side of the brain
endothelium is often negatively charged. This should be taken into account as an additional
way to facilitate the penetration of fatty acylated proteins across the BBB. For example,
cellular binding might increase when the modified protein itself contains a polybasic motif
which in addition to lipid carrier serves as an anchor generating stable and sufficient
hydrophobic interactions with cell membrane [23]. Furthermore, most free fatty acids are
bound to albumin. It is conceivable that circulating fatty acylated proteins bind with
albumins as well, which can affect the PK profile and subsequent BBB penetration.
Moreover, the brain PK profile and brain region distribution of the fatty acylated proteins
could be significantly affected by possible interactions of the fatty acid residues with the
intrinsic receptors for the fatty acids in the CNS. For example, free fatty acids can activate
an endogenous G protein-coupled receptor (GPCR), which acts as a nutrient sensing
apparatus to regulate nutrient balance [61]. Some of the GPCRs are expressed in the brain
[62]. However, the concentration of the circulating fatty acylated proteins may be below the
micromolar level, a concentration needed for the receptor activation. This would negate a
possibility of potential side effects of the fatty acylated proteins associated with the effect on
the GPCRs.
Polymer-protein conjugates
Conjugation of proteins with natural and synthetic polymers has been researched for several
decades and led to important pharmaceutical products. Many studies have focused on
modification of proteins with hydrophilic oligosaccharides such as polysialic acid (PSA),
[63] dextrin [64–67] hyaluronic acid [68] as well as water-soluble synthetic polymers such
as N-(2-hydroxypropyl)-methacrylamide (HPMA) [69] and poly(ethylene) glycol (PEG)
[70–79]. Most of these protein-polymer conjugates displayed prolonged circulation time and
improved stability as compared to native proteins. One of the early examples of such
conjugates is Streptodecase, which represents streptokinase, a plasminogen activator
enzyme, immobilized on a polysaccharide dextran carrier [25]. Streptodecase has been
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marketed since 1980 in Soviet Union (and then in Russia) as an injectable long-acting
fibrinolytic drug. In 1982a group of scientists including Vladimir Torchilin was awarded the
USSR Lenin prize for the development of immobilized enzyme therapeutics for heart
diseases, such as Streptodecase.
Perhaps to date the most successful approach to improve bioavailability of proteins through
their conjugation with water-soluble polymers is the covalent modification of proteins with
PEG chains, known as “PEGylation”. Frank Davis and colleagues have pioneered
PEGylation in the 1970s [71]. Using catalase and albumin as model proteins, they showed
that attachment of PEG (1900 or 5000 Da) to these proteins prolonged their circulation,
increased their serum stability and reduced their immunogenicity [80,81]. Since then
PEGylation has been widely used to modify various proteins and has tremendously helped
advance the development of novel protein therapeutics [63]. In 1981 Dr Davis and his
former student Dr Abraham Abuchowski founded Enzon Corporation, which became
publicly traded in 1984 and then brought to the market the first two PEGylated protein
products, PEG-adenosine deaminase in 1990 and PEG-L-asparaginase in 1994. Following
this breakthrough over a dozen of PEGylated protein drugs have been approved for clinical
use in the United States and other countries (Table 2).
Conjugation of proteins with hydrophobic polymers for medical applications has been
relatively less researched. One polymer-protein conjugate brought to market in Japan in
1990s was neocarzinostatin (NCS) conjugated with hydrophobic poly(styrene-co-maleic
acid) (SMA) [82–84]. The drug is also known as Zinostatin or Smancs and is marketed in
Japan by Astellas Pharma. It was developed by Hiroshi Maeda and colleagues who intended
to prolong the circulation time of NCS for the improvement of its antitumor activity. The
modified NCS was dissolved in its oil-based carrier Lipidol and administered via hepatic
artery injection as an oily formulation. Higher hydrophobicity of SMANCS appeared to
result in a much longer circulation of NCS, efficient accumulation of NCS in both tumor and
lymphatic tissue and improvement in its antitumor activity against hepatocellular carcinoma
[84]. Following-up studies from the same group and others further showed that SMA
modification increased serum circulation of human granulocyte colony-stimulating factor
(rhG-CSF), cell adhesive laminin peptide YIGSR and superoxide dismutase (SOD) [85–87].
It is noteworthy that different from PEGylation, the prolonged in vivo plasma half-life of
SMA modified proteins was mostly attributed to the non-covalent albumin binding of its
attached SMA polymer, which thereby prevented a rapid renal excretion [88]. Whether or
not such modification improves the delivery of protein to the brain, however, has not been
reported.
Despite progress in development of protein conjugates with hydrophilic and hydrophobic
polymers it had not been until relatively recently when the amphipihlic block polymers
containing both hydrophilic and hydrophobic chains were first used for chemical
modification and delivery of proteins. However, once implemented this approach resulted in
unexpected and important consequences in polymer therapeutics, particularly in delivering
proteins to the brain, which is described later.
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Proteins modified with amphiphilic Pluronic block copolymers
Pluronic molecule consists of poly(ethylene oxide) (PEO, same as PEG) and poly(propylene
oxide) (PPO, same as PPG) segments arranged in a basic A-B-A structure: PEO-PPO-PEO
(Table 3, A). These commercially available polymers are widely used in a variety of clinical
applications and are listed in the U.S. and British Pharmacopoeia under the name
“poloxamers” as excipients. Changing the number of ethylene oxide and propylene oxide
units generates a variety of polymers differing in size, molecular mass and hydrophobicity.
Above certain critical temperatures the PPO chains become insoluble and tend to aggregate
in aqueous media while the PEO chains can remain soluble. As a result, a unique feature of
Pluronic molecules is their ability to self-assemble into micelles above the critical micelle
temperature (CMT) and critical micelle concentration (CMC), or to form temperature-
responsive gels at relatively high concentrations.
The use of Pluronic block copolymers in pharmaceutical formulations has a long history.
Such formulations include Pluronic-based gels and blends used in delivery and sustained
release systems for low molecular mass drugs and biomacromolecules, including proteins
[95]. The surface-active properties of Pluronic block copolymers have been utilized for
stabilization of various pharmaceutical dispersions, such as water-in-oil and oil-in-water
emulsions [96,97] as well as Pluronic-based core-shell nanoparticles [98]. Pluronic-based
polymeric micelles have been used for delivery of solubilized drugs and were first in class
polymeric micelle drugs that underwent clinical trials [99]. Recent work also indicates that
simple coating drug-encapsulated nanoparticles with certain poloxamers can significantly
increase drug accumulation in the brain [100–102]. Interestingly, according to Frank Davis
the idea of PEGylation actually originated from Pluronic block copolymers [71]. He had
chosen PEG, rather than any other hydrophilic polymer for protein modification, because he
found that a structurally related Pluronic was already in use by physicians. At that time,
Pluronic was infused to patient blood to prevent the formation of lipid embolisms during the
course of vessel surgery.
Perhaps, the first protein-Pluronic covalent conjugates described were insulin and antibodies
attached to Pluronic analogs, which were used as targeting moieties for the delivery
polymeric micelles to the brain [103]. Pluronic P85 is an amphiphilic block copolymer with
a molecular mass of ca. 4600 Da having approximately equal by mass content of PPO and
PEO chains. The unconjugated Pluronic P85 was formulated with a neuroleptic drug,
haloperidol in the form of polymeric micelles and then blended either with Pluronic P85
modified insulin or antibodies. As a result, the protein molecules incorporated into the PEO
shell of the polymeric micelles while the solubilized drug remained in the micelle core
formed by PPO chains. The antibodies used in this study included either brain specific
antibodies against alpha-2-glycoprotein (α2-GP) or brain non-specific antibodies against
alcohol dehydrogenase (ADG). The micelles were intraperitoneally administered into mice,
and the haloperidol biological activity was determined. Notably, all haloperidol micelle
formulations exhibited better central response than the haloperidol alone. Among the micelle
groups, the most pronounced increase of haloperidol action was observed with the micelles
linked to the brain specific antibody, followed by the micelles linked to insulin, and then
non-specific antibody or untargeted micelles. Further studies using a similar micelle system
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but incorporating fluorescence dye confirmed that the dye was in fact delivered to the brain
parenchyma [104].
More studies then followed to understand how Pluronic block copolymers interacted with
the BBB. Interestingly, selected copolymers such as Pluronic P85 were identified as potent
inhibitors of P-glycoprotein (Pgp), a multidrug efflux transporter expressed in the brain
endothelium [105]. Therefore, exposure to these copolymers increased permeability of Pgp
substrates across the BMEC and enhanced entry of Pgp-substrates into the brain [106–108].
Moreover, fluorescently labeled Pluronic P85 and some other copolymers administered
intraperitoneally in mice were shown to localize in the brain tissues [109,110]. The 3H-
labeled Pluronic P85 following intravenous injection in mice was quantified in the brain,
albeit at less than 1% of inj/g [109,110]. The mechanism of the cellular entry of Pluronic
P85 has been elucidated, suggesting that the copolymer single chains co-localize with
caveolin 1 and enter cells through a clathrin-independent but caveolae-dependent pathway
[111]. A more recent study further demonstrated that BMEC and primary neurons take up
Pluronic P85 in a fashion reminiscent of the bacterial pathogen, Cholera toxin B trafficking
[112]. Although in BMEC the caveolae served as a primary entry site for the copolymer
single chains, in the primary neurons devoid of caveolae, the copolymer was exploiting
caveolae- and clathrin-independent routes: the uptake started from accumulation of Pluronic
P85 in the cell body and was followed by anterograde trafficking of polymer towards axons/
dendrites endings. The similarity of the copolymer’s trafficking with that of biological
pathogens was reinforced since both bypassed early endosomes/lysosomes and transported
to the endoplasmic reticulum. The copolymer finally reached the mitochondria that served as
its final destination.
Parallel to these studies of single copolymer chains trafficking, Pluronic P85 was directly
attached to proteins with the goal to increase protein delivery to the brain [13,31,90–92]
(Table 3). Initially, the BBB impermeable enzyme, HRP, was used as a model protein [31].
The copolymer was attached to the protein amino groups through either degradable
(containing disulfide bond) or non-degradable linkers. The in vitro study of the transport of
the HRP conjugates across the BBMEC monolayers revealed that while all types of the
conjugates displayed increased permeability compared to the unmodified protein, the
conjugates with the disulfide bonds were the most efficacious. Hence, such conjugates were
further selected for the PK studies in vivo. In these studies the brain delivery of the
radioactively labeled unmodified and Pluronic-conjugated HRP was evaluated after their
intravenous administration to mice by determining the brain/ serum ratios. The analysis of
the PK of the modified HRP did not reveal any significant increase in the serum half-life
compared to the native enzyme (possibly because HRP itself is already a highly stable and
long-circulating protein). However, as a result of the modification the influx rate of HRP at
the BBB was increased by 4-fold, which led to an improved brain uptake of the protein over
time (1.8-fold increase at 200 min following injection). At the same time the modification
did not change the volume of distribution of HRP, suggesting that the tissue sequestration of
the conjugate was minimal. This indicates that such modification approach may result in an
improvement in protein delivery compared to the protein fatty acid acylation, which in the
case of HRP increased the volume distribution. The capillary depletion study further
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revealed that the majority of Pluronic modified HRP transported in the brain parenchyma
rather than remained entrapped in the brain capillary [31]. Therefore, Pluronic modification
enabled a BBB impermeable protein to enter the brain, albeit the influx rate and brain uptake
of the modified HRP was less than that commonly observed for proteins that enter the brain
through a BBB transporter. Further studies using BBMEC monolayers established a
relationship between the structure of the block copolymer and the cell membrane binding
and transport capability of the modified HRP [90]. The protein was conjugated to the
copolymers that differ in the molecular mass and hydrophobicity (Pluronic L81, Pluronic
P85, Pluronic L121, and Pluronic P123). Albeit the conjugation chemistry was the same as
in the previous study the modification of the amino groups resulted in fairly heterogeneous
products. Unfortunately, the post-modification purification, such as ion exchange
chromatography, could not isolate HRP linked to a single polymer chain from the remaining
species. Comparisons were then made for HRP conjugates with the average modification
degrees ranging from 1 to 3. Nevertheless, the study concluded that Pluronic P123, the
copolymer having long PPO and PEO chains was the least effective in improving the HRP
binding and transport in the cells. Although HRP modifications with the remaining three
copolymers all enhanced the protein binding to the cells, the permeabilities of the modified
proteins in the BBMEC monolayer were quite different. The greatest improvement in the
transport across the BBMEC monolyaers was observed in the case of HRP modified with
Pluronic L81, followed by Pluronic L121 and then Pluronic P85. Thus, it appears that the
copolymers with the shortest PEO blocks (Pluronic L81 and Pluronic L121) are more
favorable in terms of cell transport of the modified protein compared to the copolymer with
the relatively longer PEO block (Pluronic P85) [13,90].
Based on these findings we further focused on the delivery of an antioxidant enzyme,
superoxide dismutase 1 (SOD1), which can exert therapeutic effect in the brain by
scavenging superoxide ions. There is a considerable body of evidence that blocking
angiotensin II (AngII) central signaling, in particular by attenuating the AngII-induced
increase in superoxide in the CNS could be beneficial for treatment of neurocardiovascular
diseases, such as hypertension and heart failure [113–118]. However, delivery of antioxidant
enzymes, such as SOD1 to central neurons is hindered by two barriers – the BBB and the
neuronal cell membrane, and may be further complicated by poor serum bioavailability of
the native protein. Since modification of SOD1 with the linkers containing a disulfide bond
led to the enzyme inactivation, we modified SOD1 with Pluronic L81 and Pluronic P85
using a non-degradable linker [91]. In this case the protein conjugates modified by only one
polymer chain were isolated by size exclusion chromatography. An AngII sensitive neuronal
cell model was used to evaluate the intracellular delivery and efficacy of the resulting
conjugates [91]. Of the two modified SOD1 forms the protein modified with Pluronic L81
exhibited more efficacious transport into the cells than the protein modified with Pluronic
P85. A PEGyalted form of SOD1 also included in these studies did not show increased
neuronal uptake compared to the unmodified enzyme. The in vivo activity of SOD1
modified with Pluronic P85 was evaluated by recording the AngII-evoked pressor response
in a normal rabbit model [90]. After a single intracarotid injection the modified SOD1
attenuated the AngII-induced increase in arterial pressure for as long as day 1, 2, 3 and up to
day 7; whereas no reduction in the pressor response was observed in rabbits administered
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with the native SOD1 by the same route and dose. In the heart failure rabbit model, our
preliminary data also showed that intracarotid injection of the modified SOD1 led to a
significant attenuation of AngII-induced response at day 3, which lasted up to day 7;
whereas the inhibition of the pressor response in the native SOD1 treated group was
minimal.
Another therapeutic protein that was modified by Pluronic block copolymers is leptin, a 16
kDa gut-brain hormone that exerts its anti-obesity activity exclusively within the brain.
Although endogenous leptin is rapidly transported across the BBB by way of a specific,
saturable transport system [119], systemic delivery of leptin to the brain for obesity
treatment was not successful because of the poor bioavailability of leptin itself and the
defect of its transport system that occurs in obesity [120–122]. We, therefore, proposed to
modify leptin with Pluronic in an attempt to overcome the transport deficiency and improve
leptin systemic delivery. Modification of leptin by Pluronic P85 was similar to that of SOD1
except that a biodegradable disulfide linker was used to bridge leptin and the copolymer. We
have speculated that such a leptin conjugate with cleavable disulfide bonds might act as a
prodrug that preserves similar serum stability as the conjugate containing the stable linker
but performs better within the brain since it can activate its receptor after releasing free
leptin. The first generation of Pluronic P85-modified leptin (leptin-P85) was produced using
native mouse recombinant leptin and purified using the same procedure as for SOD1
conjugates [92]. Unfortunately, the purification failed to separate unmodified and modified
leptin because of the interference of unreacted dimer form of leptin that eluted at the almost
same time as the modified leptin. Therefore, our initial work focused on this fairly
heterogeneous leptin-P85 conjugate and studied its brain PK and in vivo biological activity
[92]. This modified leptin circulated 3 times longer than the native leptin and was
transported across the BBB at a similar rate as the native leptin. Importantly, the BBB
transport of the iodinated leptin-P85 conjugate was not inhibited by excess of unlabeled
leptin or unlabeled conjugate, which suggests that this conjugate is transported to the brain
through a non-saturable and leptin-transporter independent mechanism. The capillary
depletion studies further confirmed that the majority of leptin-P85 accumulated in the brain
parenchyma. Tissue distribution studies discovered that other than brain, modification also
increased leptin uptake in heart, muscle and stomach but not in liver, lung and kidney.
The in vivo activity of the leptin-P85 conjugate was evaluated by measuring the acute
feeding response in normal body weight mice. Both leptin-P85 and native leptin inhibited
food intake of CD-1 mice following intracerebral ventricular administration. However, the
minimum effective dose for leptin-P85 was 4- to 8-fold higher than that of the leptin. The
food intake was significantly reduced after intravenous administration of leptin-P85 [92].
Moreover, our on-going studies showed that this leptin-P85 conjugate was also effective in
reducing the food intake and decreasing the body weight in ob/ob mice and diet-induced
obese mice. We also established a method to optimize this leptin-P85 conjugate with aiming
to reduce the heterogeneity and improve the binding activity. Currently we are able to obtain
more homogenous leptin-P85 conjugates. Depending on the modification degree, leptin
attached by a single Pluronic P85 chain and leptin attached by multiple P85 chains enter the
brain using different mechanisms but both show longer circulation times compared to the
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native leptin. These two conjugates are transported across the BBB at much lower rates than
the native leptin but still significantly faster than albumin [123]. Altogether, these results
indicate that Pluronic modification indeed enables leptin to enter the brain and improves
leptin serum bioavailability. However, only conjugates containing multiple copolymer
chains show a capability to overcome leptin transporter deficiency and enter the brain in a
manner independent of the leptin BBB transporter.
As of today brain PK data suggest us that the modification of proteins with the Pluronic
copolymers, on the one hand acts similarly to PEGylation, being able to improve the protein
circulation time and stability, and on the other hand, can facilitate the delivery of the
modified proteins across the biological barriers. The transport of Pluronic modified proteins
in the BBB most likely does not involve an active transport mechanism. Pluronic P85 alone
did not show any specific transporter binding capability at the luminal side of the BBB
[124]. Moreover, the leakage of the conjugates through disruption of the tight junctions in
BMEC should be excluded because the BBB remained intact in vitro (as follows from the
parallel studies of the permeability of a paracellular marker, 3H mannitol) [90], as well as in
vivo (as is clear from the simultaneous measurements of the brain uptake of co-injected
iodinated albumin) [92]. Quite to the contrary, the observed influx rates of the modified
proteins and the evidence of their non-saturable brain uptake strongly support a diffusion-
based mechanism for their transport. Interestingly, the brain transport rate of both native
leptin and leptin-P85 is 2- to 3-fold higher in mice with perfusion than that of the mice
without perfusion [125]. This suggests that serum attenuates the transport of the native
protein and conjugate across the BBB. However, 3H-labeled P85 did not interact with any
serum protein [126]. Therefore it is unlikely that serum contributes to the transport of the
Pluronic modified protein in the BBB by interacting with the copolymer chains.
The data on the mechanisms of the cellular trafficking of Pluronic P85 alone, makes it
tempting to suggest that similar mechanisms are also realized in the case of the Pluronic
modified proteins, which could utilize the caveolae-mediated endocytosis or caveolae- and
clathrin-independent pathway [111]. Our unpublished data suggest that in MDCK cells
SOD1 co-localizes with transferrin and to a notably lesser amount with Cholera toxin B. In
contrast, the SOD Pluronic P85 conjugate co-localizes equally with both endocytosis
markers. Hence modification of SOD1 with Pluronic may shift this protein from the
clarthrin pathway towards the caveolae pathway. This is further reinforced by an increased
colocalization of the conjugate with caveolin-1. Future studies must further tackle the
transport mechanisms of Pluronic modified proteins across the BBB. These mechanisms
could be quite complex and depending on the type of the protein may include receptor
mediated endocytosis, as well as lipid rafts (Figure 2). Various lipid rafts have been
identified in brain the endothelium and they are believed to regulate tight junction function,
transporter activity and endothelial cell adhesion [127]. Lipid-enriched membrane
microdomain compartmentalization at the luminal side of the BBB allows for the apicobasal
polarity [128]. Whether any of such lipid rafts are involved in binding and trafficking of
Pluronic modified proteins in BBB is an important question to be addressed in the future.
Such future studies could also provide a rationale for the design of novel and improved
conjugates of proteins with amphiphilic block copolymer for CNS delivery.
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Proteins modified with amphiphilic poly(2-oxazoline)- based block
copolymers
Poly(2-oxazoline)s (POx) is a prominent member of pseudo-polypeptides that can be
synthesized by living cationic ring-opening polymerization of 2-oxazoline monomers. The
well-defined structure and narrow polydispersity of POx polymers along with their low
toxicity make them an attractive material for various biomedical applications. Most of the
early studies using these polymers in therapeutics and drug delivery applications focused on
hydrophilic homopolymers poly(2-methyl-2-oxazoline) (PMeOx) and poly(2-ethyl-2-
oxazoline) (PEtOx). Similar to PEG such hydrophilic POx polymers once grafted to
nanoparticles or conjugated to biomacromolecules confer stealth behavior and
biocompatibility. Specifically, modification of proteins with water-soluble POx was shown
to improve protein stability and peripheral PK [129,130]. POx conjugation technologies
have reached the clinical evaluation stage. Thus a small molecule drug, rotigotine
conjugated to POx polymer displayed significant therapeutic response in pre-clinical
Parkinson disease model and due to a long circulation the conjugate is being developed as
once a week administration to treat Parkinson patient [131].
Helmut Ringsdorf who suggested to one of us that we could collaborate with Robert
Luxenhofer and Rainer Jordan precipitated our interest in POx chemistry [132]. The
collaboration initially focused on polymeric micelles formed by amphipiplic copolymers
containing hydrophilic PMeOx or PEtOx block and hydrophobic, for example, poly(2-
butyl-2-oxazoline) (PBuOx) block (Table 3B). Such micelles have been shown to display
unprecedented high capacity for solubilization of very poorly soluble drugs and drug blends
[132,133]. Consequently, such micelles emerged as a powerful platform for drug delivery.
Parallel studies explored the cellular uptake of such POx based block copolymers [134] and
some of these experiments revealed that similar to Pluronic P85, selected POx-based block
copolymers co-localized in the cells with the Cholera toxin B. Based on that we
hypothesized that these block copolymers may employ a lipid-raft mediated mechanism for
the cell entry and pretty much like Pluronic block copolymers can carry proteins inside of
the cells. This inspired us to dedicate effort to the development of POx-protein conjugates
for brain targeting [133,134] (Table 3). Conjugation of POx block copolymers to proteins
followed the general procedure used to produce the protein-Pluronic conjugates, except that
generation of terminal mono-amine functionalities in the copolymers was conveniently
realized by terminating POx polymerization with piperazine. As in the previous cases initial
work used HRP as a model protein. The studies in two cell lines, MDCK and Caco-2,
revealed that modification of HRP with amphiphilic di-block copolymers, poly(MeOx-b-
BuOx) and poly(EtOx-b-BuOx), has greatly increased the cellular uptake of the protein
compared to unmodified HRP [93]. Interestingly, the modification of HRP with the random
copolymer, poly(EtOx-co-BuOx) had little if any effect on the internalization, while
hydrophilic homopolymer PMeOx clearly inhibited the cellular uptake compared to
unmodified HRP.
Based on these findings the two amphiphilic di-block copolymers were selected to modify
SOD1 [94]. The conjugates were purified by size exclusion chromatography yielding SOD1
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attached by 2–3 polymers and retaining 30–50% activity. Interestingly, SOD1 modified with
poly(EtOx-b-BuOx) exhibited higher uptake in CATH.a neurons than that of SOD1
modified with poly(MeOx-b-BuOx). Similar to Pluronic modified SOD1, SOD1-
poly(EtOx-b-BuOx) conjugate penetrated the neuronal cell membrane in an active form, as
demonstrated by the inhibition of AngII-induced increase in intracellular superoxide. The
SOD1-poly(EtOx-b-BuOx) mainly utilized lipid raft/caveolae mediated endocytosis to
internalize into CATH.a neurons, which was similar to the internalization of the copolymer
alone. The trafficking itinerary of this conjugate included its accumulation in endoplasmic
reticulum and mitochondria [94].
The in vivo brain PK study demonstrated that poly(EtOx-b-BuOx) modification enabled
otherwise BBB impermeable SOD1 to cross the BBB and elongated the protein serum
circulation time by 2-fold. The transport appeared to be non-saturable and the majority of
the transported protein was in the brain parenchyma. The influx rate was greater than that of
albumin, albeit notably less than that of substances that employ active transport systems to
cross the BBB. The improvement in the brain penetration and serum circulation of SOD1-
poly(EtOx-b-BuOx) were similar to those that were observed with Pluronic P85 modified
HRP, suggesting that both copolymers may play a similar role in CNS delivery [31,94].
However, due to its purity, narrow size distribution and stability POx may be superior as an
agent for protein modification compared to Pluronic. Albeit detailed discussion of the
versatile synthetic POx platform is beyond the scope of this review [132], we would like to
point out that the living cationic ring-opening polymerization of 2-oxazolines can produce
well-defined amphiphilic POx. For example, poly(EtOx-b-BuOx) used in the above studies
was synthesized by sequential block copolymerization of EtOx with BuOx, resulting a
polydispersity index of 1.09. In contrast, as a chemical product, Pluronic block copolymers
are relatively polydisperse and often contain considerable admixtures of a diblock
copolymer. Synthesis of Pluronic starts from polymerization of propylene oxide in the
presence of alkaline catalysis to generate a bifuntional PPO macroinitiator followed by
adding ethylene oxide to form symmetric PEO blocks [135]. The reaction conditions and
copolymer manufacturing are well established and are fairly inexpensive. However in
commercial synthesis procedure a side reaction also occurs and thereby generates allyl-
attached PPO-PEO. Our unpublished mass spectra and NMR data revealed the presence of
diblocks in commercial samples of Pluronics. Following purifications used in the generation
of mono-amine Pluronic derivatives, most of the diblocks can be removed, albeit careful
elution and precise characterization of the collected fractions are required. Occasionally the
residual mono-amine di-block copolymers are generated that can attach to proteins in a
subsequent conjugation step, attributing to the heterogeneity of the final product. Thus,
refining the chemistry would be needed to produce more structurally defined Pluronic-
protein conjugates, while in case of the Pox-based conjugates, the synthesis may be less
challenging.
Conclusions
Modification of proteins with hydrophobic moieties enhances protein interactions with
physiological membranes and protein uptake in cells. Both fatty acylation proteins and
conjugation of proteins with amphiphilic block copolymers can increase protein residence in
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peripheral circulation and permeability at the BBB. Although the underlying mechanisms
for these phenomena may differ and are still under investigation, preclinical brain PK and
efficacy studies strongly support the benefits of both strategies and their potential for
improved brain delivery of various proteins. The case in point, a fatty acylated GLP-1 has
been successfully tested in Phase III clinical trials for the treatment of obesity. This has
stimulated further studies on fatty acylation of the gut-brain hormones. Selected Pluronic
block copolymers are widely used in pharmaceutical industry as excipients. Likewise POx
polymers appear to be relatively safe and soon will reach clinical evaluation stage.
Modification of several proteins with these polymers has resulted in improved blood
circulation and CNS delivery. One should expect that these protein modification
technologies and products will also advance the clinics.
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Methods of protein/peptide modification by fatty acid. Chemical acylation can be achieved
in either aqueous (A and B) or organic (C and D) solution. Reaction in aqueous solution in
general better preserves protein activity than in organic solvent. However, fatty acids do not
solubilize well in aqueous solution and the obtained products often show low yield with high
heterogeneity (A). Increasing fatty acid solubility by adding detergent to the aqueous
solution can result in a relatively higher yield and more homogeneous product (B). Reacting
protein/peptide with fatty acid directly in organic solvent is not recommended because of
protein inactivation and solubility issues (C). However, reacting protein with fatty acid using
a hydrated reverse micelle system in organic solution proceeds efficiently and in most cases
allows recovering more-or-less uniformly modified protein retaining relatively high activity
(D). A site-specific fatty acylation can be achieved via enzymatic catalysis. Endogenous
ghrelin has shown to be octanoylated specifically at the serine 3 position, a post-translation
step that is catalyzed by ghrelin O-acylatransferase (GOAT) (E). Since organic solvent has
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less impact on peptide activity, fatty acylation of short sequence peptides can be done during
solid phase synthesis cycle, allowing for a clean product with high yield (F).
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Hypothetical mechanisms of the blood to brain transport of Pluronic conjugated proteins.
(A) In a protein modified with a single Pluronic molecule the block copolymer hydrophobic
chains (PPO) bind to lipid rafts resulting in protein transport across the BBB. (B) The
protein modified with a single Pluronic molecule is capable of binding with the BBB
transporter as well as lipid rafts in the BBB. Both mechanisms lead to the transport across
the BBB albeit the protein transporter makes the greater contribution (likely case of leptin-
P85 with single Pluronic chain attached). (C) In a protein modified with multiple Pluronic
molecules the PPO chains bind to lipid rafts resulting in protein transport across the BBB.
(D) The protein modified with a multiple Pluronic molecules binds with lipid rafts, which
serve as major route for the conjugate CNS entry. The binding of this protein with its
transporter is either inhibited or does not result in efficient transport across the BBB (likely
case of leptin-P85 with multiple Pluronic chains attached).
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